Role of transcription factors in the transdifferentiation of pancreatic islet cells

Talitha van der Meulen1 and Mark O Huising1,2
1Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, and 2Department of Physiology and Membrane Biology, School of Medicine, University of California, 193 Briggs Hall, One Shields Avenue, Davis, California 95616, USA

Abstract

The α and β cells act in concert to maintain blood glucose. The α cells release glucagon in response to low levels of glucose to stimulate glycogenolysis in the liver. In contrast, β cells release insulin in response to elevated levels of glucose to stimulate peripheral glucose disposal. Despite these opposing roles in glucose homeostasis, α and β cells are derived from a common progenitor and share many proteins important for glucose sensing and hormone secretion. Results from recent work have underlined these similarities between the two cell types by revealing that β-to-α as well as α-to-β transdifferentiation can take place under certain experimental circumstances. These exciting findings highlight unexpected plasticity of adult islets and offer hope of novel therapeutic paths to replenish β cells in diabetes. In this review, we focus on the transcription factor networks that establish and maintain pancreatic endocrine cell identity and how they may be perturbed to facilitate transdifferentiation.

Key Words
- α cell
- β cell
- transdifferentiation
dedifferentiation
- ARX
- PAX4
- PDX1
- NKX2-2
- FOXO1
diabetes

Introduction

The pancreatic islets consist of several endocrine cell types including insulin-producing β cells, glucagon-producing α cells, somatostatin-producing δ cells, pancreatic polypeptide-producing PP cells, and ghrelin-producing ε cells. The β cells are active under conditions of nutrient excess, particularly high blood glucose levels, and secrete insulin, which has peripheral actions on liver, muscle, and fat tissues that reduce blood glucose (Thorel et al. 2010, Lin & Accili 2011, Leto & Saltiel 2012). Insulin is functionally opposed by glucagon, which promotes liver glycogenolysis to prevent hypoglycemia during fasting or exercise (Rammnanan et al. 2011). Products of β cells inhibit α cell secretion (Franklin et al. 2005), while α-cell-derived glucagon, paradoxically, activates β cells to secrete insulin (Samols et al. 1965, Kawai et al. 1995). The δ cells are generally considered to be the brake on islet secretion as somatostatin inhibits the release of both insulin and glucagon (Strowski et al. 2000, Hauge-Evans et al. 2009), thereby preventing large swings in blood glucose levels. It was generally thought that the endocrine cell types present in the islet were distinct and terminally differentiated populations. However, recent observations indicate that, under certain conditions, pancreatic cells of one type can transdifferentiate into another. This review focuses on such interconversions between the various islet endocrine cells and does not discuss in detail the ability of other pancreatic cells, such as acinar cells, to transdifferentiate into β cells following viral transduction (Zhou et al. 2008) or in
response to soluble factors (Baeyens et al. 2014). Two apparently distinct pathways have been described by which transdifferentiation of islet endocrine cells takes place, i.e., where a hormone-expressing islet cell converts into a hormone-expressing islet cell of a different type. One is direct transdifferentiation that proceeds via a double-hormone-positive intermediate cell (Lu et al. 2010, Thorel et al. 2010, Papizan et al. 2011, Yang et al. 2011). The other involves loss of hormone expression during a process of reversion to a precursor-like state before differentiation into a hormone-positive cell of a different type (Jonas et al. 1999, Talchai et al. 2012, Wang et al. 2014). Whether these different phenotypes represent mechanistically distinct transdifferentiation processes, or merely represent different gradations of a single transdifferentiation spectrum is not clear at this time and cannot always be distinguished by lineage-tracing approaches, which are best suited to evaluate the end result of the transdifferentiation process. It is clear, however, that the process of transdifferentiation of islet endocrine cells has generated considerable excitement as a potentially novel strategy for treating diabetes. While diabetes is traditionally cast as a disease of relative (type 2) or absolute (type 1) insufficiency in β cell mass, it is less appreciated that hyperglucagonemia secondary to the loss of the normal inhibitory tone on α cells from β cells contributes to the etiology of diabetes by aggravating hyperglycemia (Franklin et al. 2005, Unger & Cherrington 2012). Despite their opposing roles in the maintenance of a dynamic equilibrium of blood glucose levels, α and β cells are derived from a common progenitor. They continue to share expression of many transcription factors and genes for glucose uptake and glycolysis, stimulus–secretion coupling, and hormone exocytosis (Benner et al. 2014). This resemblance makes non-β endocrine cells the cell types that are most closely related to β cells and makes them prime candidates to target for conversion into β cells (Fig. 1).

Figure 1
Development and maintenance of α and β cells from a common progenitor (A) require intricate networks of transcription factors. Transcription factors and hormones specific to β (red) and α (green) cells are indicated. Despite their opposing functions in the regulation of blood glucose levels, α and β cells continue to share the expression of many transcription factors (black). Specificity of gene expression was determined by significant (P < 10⁻⁵) enrichment in one cell type compared with the other (B). This figure was adapted from Benner C, van der Meulen T, Caceres E, Tigyi K, Donaldson CJ & Huising MO 2014 The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15 620, published as an open access article by Biomed Central.
Herein, we will provide an overview of the recent literature on the differentiation and transdifferentiation of β and α cells, based largely on experimental observations of transgenic and knockout mouse models, with emphasis on the transcription factors that are implicated in transdifferentiation of β and α cells, before we address the application of transdifferentiation in managing diabetes.

Transcription factors in early pancreas formation

The pancreas is first identified by the transcription factor pancreatic and duodenal homeobox 1 (PDX1), which marks the pancreatic anlage starting at embryonic day 8.5 (E8.5) in the mouse (Ohlsson et al. 1993, Guz et al. 1995). The absolute requirement of PDX1 for pancreas development is evident from global loss of PDX1, which results in the absence of a pancreas at birth (Jonsson et al. 1994, Offield et al. 1996). A hypomorphic allele of PDX1, created by the deletion of some regulatory sequences for PDX1 expression, results in a remnant pancreas with ductal and acinar cells, but a relative lack of endocrine cell development, with α cells being least affected (Fujitani et al. 2006). PDX1 expression is quickly followed by expression of the basic helix–loop–helix protein pancreas-specific transcription factor 1a (PTF1A; Krapp et al. 1996, Hald et al. 2008), forkhead box O1 (FOXO1; Kitamura et al. 2009), NK2 homeobox 2 (NKX2-2; Sussel et al. 1998), and NK6 homeobox 1 and 2 (NKX6-1 and NKX6-2 (Henseleit et al. 2005) respectively). PTF1A is initially expressed in progenitors comprising the early pancreatic epithelium but subsequently becomes restricted to the exocrine acinar cells and their precursors (Krapp et al. 1996, Kawaguchi et al. 2002, Hald et al. 2008, Pan et al. 2013). PTF1A expression is repressed by the NKX6 proteins and PTF1A conversely represses expression of the NKX6 genes, thereby segregating the acinar lineage from the ductal/endocrine lineages (Schaffer et al. 2010). FOXO1 and PDX1 continue to be expressed in the same pancreatic cells, but either one or the other is localized to the nucleus (Kitamura et al. 2002, 2009). FOXO1 inhibits PDX1 function (Kitamura et al. 2002), yet the expression of FOXO1 is important for maintenance of normoglycemia as animals age (Talchai et al. 2012). The transcription factor that marks the earliest progenitor exclusive to all endocrine cells within the pancreas is the basic helix–loop–helix transcription factor neurogenin 3 (NGN3; Gu et al. 2002). NGN3 is required for endocrine cell formation (Gradwohl et al. 2000) and initiates a new set of developmental programs as expression of many transcription factors that are very important for endocrine cell lineage differentiation and maintenance depend on NGN3. These factors include the LIM homeobox protein islet 1 (Is1), paired box 4 and 6 (PAX4 and PAX6), aristaeles-related homeobox (ARX), and neuronal differentiation 1 (NEUROD), which are all lost in Ngn3-deficient mice (Gradwohl et al. 2000, Collombat et al. 2003). The competency of progenitors changes with time such that NGN3+ cells that arise early in development preferentially differentiate into glucagon+ cells while later-born NGN3+ cells give rise to insulin+ or somatostatin+ cells (Johansson et al. 2007). The number of differentiating NGN3+ cells is limited by lateral inhibition via Notch signaling (Apelqvist et al. 1999, Murtaugh et al. 2003). After endocrine cell fate is specified by NGN3, PDX1 becomes restricted to β cells and a subset of δ cells by E13.5 (Ohlsson et al. 1993, Peshavaria et al. 1994) and helps maintain β cell mass (Ahlgren et al. 1998). NKX2-2 and NKX6-1 expression also become progressively restricted to the endocrine compartment (Sussel et al. 1998, Sander et al. 2000). NKX2-2 marks most endocrine cells with the exception of δ cells. Deletion of NKX2-2 causes major changes in the endocrine makeup of the islets, as z and PP cells are reduced in number (Sussel et al. 1998), while β cells are replaced by ghrelin cells (Prado et al. 2004). Within the islet, NKX6-1 functions downstream of NKX2-2 and is both necessary and sufficient for β cell neogenesis during the secondary transition, a time of further differentiation and major expansion of the endocrine cell mass. By E15.5, NKX6-1 is found exclusively in β cells and scattered ductal and periductal cells (Sander et al. 2000, Schaffer et al. 2013). While NKX2-2 and NKX6-1 (and in its absence NKX6-2) are required for early endocrine cell development, including α cells (Sussel et al. 1998, Henseleit et al. 2005), NKX6-1 expression is later lost from the developing α cells. In fact, continued expression of both NKX2-2 and NKX6-1 in the β cells actually represses α cell fate via repression of ARX (see also below) to maintain β cell identity (Papizan et al. 2011, Schaffer et al. 2013). These observations are indicative of a central role of the PDX1, NKX2-2, and NKX6-1 transcription factors in the early development of β cells.

Transcription factors later in β cell differentiation

The transcription factor PAX4 is induced later than NKX2-2 and NKX6-1 and acts downstream of NGN3 (Gradwohl et al. 2000). PAX4 is necessary for normal β and δ cell development, as α and ghrelin cell numbers are increased in its
absence at the expense of β and δ cells. This indicates a fate switch of endocrine progenitors in the absence of PAX4 from β/δ to α/ε cells (Sosa-Pineda et al. 1997, Prado et al. 2004).

During the later stages of β cell differentiation, the MAFB and MAFA transcription factors play a prominent role. MAFB expression in β cells precedes an increase in PDX1 expression that marks the start of insulin transcription. In the absence of MAFB, fewer α and β cells are present, although total endocrine cell mass is not changed (Artner et al. 2007). MAFA expression follows shortly after insulin expression (Artner et al. 2006, Nishimura et al. 2006) and persists in adult β cells (Fig. 2). MAFB expression

![Figure 2](image-url)

**Figure 2**
Illustration of the pancreatic transcription networks in α and β cells. Expression of transcription factors PDX1 (A), NKX2-2 (B), NKX6-1 (C), NEUROD1 (D), MAFA (E), PAX4 (F), ARX (G), and FOXO1 (H) in β and α cells as determined by whole transcriptome sequencing (RNA-Seq), combined with chromatin immunoprecipitation data (ChIP-Seq) for PDX1 (Khoo et al. 2012), NKX6-1 (Taylor et al. 2013), and NEUROD1 and MAFA (Tennant et al. 2013). Purple arrowheads indicate binding of NKX6-1 and PDX1 to the same TAAT sequence in the NKX6-1 gene, green arrowheads indicate closely spaced but non-identical binding sites for NEUROD1, NKX6-1, and PDX1 on the NEUROD1 and MAFA genes. Blue arrowheads indicate the PDX1 and NKX6-1 binding sites on the ARX gene. NKX6-1 inhibits ARX expression via this interaction (Schaffer et al. 2013).
is lost postnatally from mouse (Artner et al. 2010) but not human (Dai et al. 2012, Riedel et al. 2012) β cells. In Mafb-deficient mice, insulin expression is reduced and delayed until MAFA becomes expressed, but the resulting insulin^+ cells lack PDX1, NKX6-1, and GLUT2 (SLC2A2) (Artner et al. 2007) and are therefore unlikely to represent true β cells. In MAFA-deficient pancreata, about one-third of β cells continue to express MAFB postnatally, which may partially compensate for the loss of MAFA (Artner et al. 2010). Nevertheless, these mice display reduced expression of several genes involved in glucose-stimulated insulin secretion and have reduced glucose tolerance (Zhang et al. 2005, Artner et al. 2010, Hang et al. 2014).

Upon β cell specification, the transcription of insulin is initiated and maintained by MAFB (Matsuoka et al. 2003), PDX1 (Ohlsson et al. 1993), NEUROD1 (Naya et al. 1995), PAX6 (Sander et al. 1997), and MAFA (Kataoka et al. 2002, Olbrot et al. 2002, Matsuoka et al. 2003). Additionally, PAX4 (until expression is lost in adult, Fig. 2), NKX6-1, and PDX1 inhibit glucagon expression (Ritz-Laser et al. 2002, Schisler et al. 2005), thereby preventing the expression of glucagon by β cells.

**Transcription factors that define the α cell**

ARX is one of the first known transcription factors to mark the α cell lineage (Fig. 2) and is required for α cell development (reviewed in Bramswig & Kaestner (2011)). In the absence of ARX, no α cells develop and the number of β and δ cells increases without affecting the total number of endocrine cells. This indicates that precursors alter their fate from α to β and δ (Collombat et al. 2003). This phenotype is exactly the converse of that seen in Pax4-deficient mice described earlier in this review. Indeed, a competitive reciprocal interaction between ARX and PAX4 is involved in the decision of cell fate between α and β cell (Collombat et al. 2003, 2005). In the absence of ARX, PAX4 expression in early development takes over the ARX domain, leading to increased numbers of β/δ cells at the expense of the α cell population. Conversely, in the absence of PAX4, ARX expression in early development expands, resulting in the opposite phenotype. When both ARX and PAX4 are lost, both α and β cells are lost, while the δ cell population persists (Collombat et al. 2005). The same holds true for mice in which both ARX and NKX2-2 are lost (Kordowich et al. 2011, Mastracci et al. 2011). From these observations, it follows that ARX is required to generate the α cell phenotype, while NKX2-2 and PAX4 are required for the β cell phenotype and are permissive of, but not required for, δ cell formation. While ARX is necessary for the early specification of the γ cell and directly maintains α cell mass (Courtney et al. 2013), it is not directly involved in glucagon expression (Gosmain et al. 2011).

**Transcription factors later in α cell differentiation**

The PAX4-related factor PAX6 is expressed by both α and β cells. Pax4-deficient mice lack α cells (St-Onge et al. 1997). In addition to its role in insulin transcription in the β cell, PAX6 also coordinates glucagon transcription in the α cell directly by binding to the glucagon promoter (Sander et al. 1997) and indirectly by inducing expression of other transcription factors such as c-Maf, MAFA, and NEUROD1, which also activate glucagon expression (Dumonteil et al. 1998, Artner et al. 2006, Gosmain et al. 2011). Moreover, PAX6 forms heterodimers with c-Maf on the glucagon promoter (Gosmain et al. 2007). A third factor that is crucial for α cell development is FOXA2. Foxa2-deficient pancreata show normal expression levels of ARX and PAX6, indicating that FOXA2 plays a role later in α cell development downstream of these transcription factors. Indeed, Foxa2-deficient pancreata display a lack of mature α cells while α cell precursors are present (Lee et al. 2005). Upon successful specification of the α cell lineage, pre-pro-glucagon expression is further promoted by FOXA1 (Kaestner et al. 1999), BRN4 (Hussain et al. 1997), and ISL1 (Wang & Drucker 1995, Du et al. 2009). Of all these transcription factors that can promote glucagon expression, expression of only two, BRN4 and MAFA, is enriched in adult mouse α cells compared with β cells, while transcripts for Pax6, Foxa2, Foxa1, and Isl1 are expressed at similar levels in mouse α and β cells (Benner et al. 2014).

**Redundant transcription factor networks**

As just described, the identity of the different pancreatic lineages is coordinated by a complex network of transcription factors that first establishes and then maintains differentiated cell identity. The transcription factor networks in the endocrine pancreas in particular are self-reinforcing, which is illustrated by key transcription factors binding regulatory elements in proximity to their own genes, as well as those of other transcription factors (Pasquali et al. 2014). They activate lineage-appropriate genes or, equally importantly, repress expression of lineage-inappropriate genes (Collombat et al. 2003, Schaffer et al. 2010, 2013, Papizan et al. 2011). Multiple transcription factors bind the same promoter and the net
effect of the individual interactions determines the transcriptional activity of a gene. This principle is illustrated for the NEUROD1, PDX1, and NKX6-1 transcription factors in Fig. 2. NEUROD1, which recognizes a different core motif from NKX6-1 and PDX1 (Seo et al. 2007), binds in close proximity to PDX1 and NKX6-1 on the promoters for NeurD1 and Mafa (Fig. 2D and E, green arrowheads). Moreover, related transcription factors recognize highly similar consensus binding sites. For example, homeobox-containing genes such as PDX1 (Liberzon et al. 2004) and NKX6-1 (Jorgensen et al. 1999, Taylor et al. 2013) recognize a core TAAT sequence, while their preference for the adjacent nucleotides is less stringent. Indeed, super-imposable peaks for PDX1 and NKX6-1 over a single TAAT sequence are evident on the NKX6-1 gene (Fig. 2C, purple arrowheads). The β-cell-specific PDX1 and NKX6-1 bind the α-cell-specific ARX gene suggesting an inhibitory effect of this binding (Fig. 2, blue arrowheads). Indeed, this is known for the NKX6-1-binding site (Schaffer et al. 2013). The resulting redundancy within the transcriptional networks may help maintain cell identity. Conversely, severe disruptions of the network compromise cell identity and contribute to dedifferentiation and transdifferentiation.

Transdifferentiation of β to α cells

Forcing β-to-α transdifferentiation by over-expression of ARX

One of the first pieces of evidence that indicated that β cells can be transdifferentiated into α cells resulted from the forced mis-expression of ARX within the pancreas. Transgenic mice were generated that expressed ARX as well as β-galactosidase from the human β-actin promoter (CAG), but only upon Cre-recombinase-mediated recombination. When ARX was expressed in all pancreas cells (by PDX1-Cre (Gu et al. 2002)) or all endocrine cells (by PAX6-Cre (Ashery-Padan et al. 2000)), pancreata showed massive reductions in β and δ cell numbers and increased α and PP cell numbers, predictably resulting in hyperglycemia (Collombat et al. 2007). The total number of endocrine cells was not altered upon over-expression in the entire pancreas, indicating that ARX is not able to divert pancreatic non-endocrine progenitor cells to an α cell fate, but instead acts on endocrine progenitors and/or their offspring. Persistent ARX expression in all β cells (using rat Ins2-Cre (Herrera 2000)) also resulted in the transdifferentiation of β cells toward α and PP cells (Collombat et al. 2007). The numbers of δ cells were unchanged. No double-hormone-positive cells were reported, indicating that β cells first down-regulated insulin before expressing glucagon (Collombat et al. 2007). Taken together, these results indicate that ARX expression not only directs endocrine progenitors toward the α and PP cell fate early in development, but also is able, later in development, to overcome an established β cell fate in favor of an α cell fate.

The importance of PDX1 for β cell identity

In addition to the importance of PDX1 for early pancreas specification, several lines of evidence suggest that PDX1 is also important for subsequent β cell generation and maintenance of β cell identity. Forced expression of PDX1 in all Ngn3 + cells and their offspring via Ngn3-Cre resulted in a reduction in the embryonic α cell population with a concomitant increase in the β cell population (Yang et al. 2011). Deletion of PDX1 slightly later in development, upon insulin expression using Cre recombinase under the control of the rat insulin 1 promoter (RIP1), resulted in the opposite phenotype: reduced β and increased α cell numbers, with many double-hormone-positive cells as well as overt diabetes by 3–5 months of age (Ahlgren et al. 1998). Cre-mediated recombination in this mouse line was inefficient and only became prominent by 3–5 weeks of age. Similar experiments using a more efficient rat insulin 2 promoter-driven Cre recombinase (RIP-Cre; Postic et al. 1999, Gannon et al. 2000) revealed earlier recombination, but essentially the same phenotype, except in an accelerated fashion and without double-hormone-positive cells. Results of lineage tracing of the recombined β cells using RIP-Cre indicated that α cells exhibited an increased proliferation rate, while β cells decreased proliferation, with no detectable β-to-α transdifferentiation (Gannon et al. 2008). However, a more recent study using tamoxifen-inducible RIP-CreER (Dor et al. 2004) to delete Pdx1 in the β cells of young adult (30-day-old) mice reaches a different conclusion (Gao et al. 2014). Herein, β cell-specific Pdx1 ablation also resulted in diabetes and increased numbers of α cells at the expense of β cells, but herein the mechanism is transdifferentiation of β to α cells (Gao et al. 2014). It is possible that the difference in outcome between these studies is attributable to the timing of the onset of PDX1 ablation, which is commensurate with the onset of insulin expression in immature β cells during embryonic development using Rip1-Cre (Gannon et al. 2008), but was started at 30 days post parturition using RIP-CreER (Gao et al. 2014) and thus did not occur until most β cells have matured (van der Meulen et al. 2012). Moreover, these two stages
differ substantially in the way new pancreatic cells can be generated. During embryonic development and up to the first 3 weeks of postnatal life, islet cells continue to be generated through neogenesis from ductal precursors (Kopp et al. 2011). In contrast, self-replication is the main mechanism by which β cell mass is maintained in the adult (Dor et al. 2004). This is indicative of an age-dependent difference in plasticity between the embryonic pancreas and the pancreas of young adult mice. Pdx1 ablation mediated by RIP-Cre and RIP1-Cre takes place during late embryonic development and can activate compensatory changes in endocrine cell ratios via both neogenesis and proliferation. In contrast, the window for neogenesis has largely closed upon tamoxifen-dependent Pdx1 ablation in RIP-CreER mice at p30 and leads to more pronounced β-to-α transdifferentiation undiluted by neogenesis. The tamoxifen-inducible RIP-CreER line offers an opportunity to directly compare the effects of PDX1 ablation at different onsets on the ensuing putative α-to-β cell transdifferentiation.

**Maintaining β cell identity through NKX2-2 expression**

Results of a recent study have highlighted the importance of NKX2-2, in particular its tinman domain, for the maintenance of β cell identity (Papizan et al. 2011). The tinman domain is located outside the homeobox domain and is not directly involved in DNA binding, but instead recruits Groucho corepressors (Muhr et al. 2001). Deletion of the tinman domain of NKX2-2 (NKX2-2TNmut/TNmut) phenocopies some aspects of total NKX2-2 deficiency, including reduced β cell mass, but the phenotype diverges in several important respects from that of global Nkx2-2 null mice. First, until E12.5, α and β cell development appears normal (Papizan et al. 2011), while NKX2-2-deficient mice have reduced α cell numbers and lack β cells altogether (Sussel et al. 1998). Secondly, in contrast to the lower α cell numbers in Nkx2-2-deficient mice, NKX2-2TNmut/TNmut pancreata show increased α cell numbers from E18.5 onward as well as an increase in the number of cells co-expressing glucagon and insulin. Yet, NKX2-2TNmut/TNmut mutants have no overt metabolic phenotype until 3.5 weeks of age when progressive hyperglycemia develops, in accordance with the increase in α cell numbers paired with a decrease in β cells (Papizan et al. 2011). Results of lineage tracing of the existing β cells using rat Ins2-Cre (Herrera 2000) indicate that at least a few of the increased population of α cells in the NKX2-2TNmut/TNmut mutant mice derive from transdifferentiated β cells, as more than 2% of α cells carried a β cell lineage mark (Papizan et al. 2011). Irreversibly labeling β cells at 3 weeks of age using a PDX1-CreER (Gu et al. 2002) reveals that mature β cells continue to transdifferentiate before any metabolic phenotype is evident (Papizan et al. 2011). While these results are very exciting, they should be interpreted with the understanding that the constitutive lack of the tinman domain of NKX2-2 could have affected β cell development in ways that were not immediately obvious from histological analyses, for example, by inhibiting final differentiation steps, potentially making it easier for these β cells to transdifferentiate. Of note is the fact that deletion of Arx from β cells in NKX2-2TNmut/TNmut mice prevented β-to-α transdifferentiation (Papizan et al. 2011), as this highlights once more the requirement of ARX for differentiation along the α cell lineage. Mechanistically, NKX2-2 achieves inhibition of the Arx promoter by forming a complex with both the de novo methyltransferase 3a (Dnmt3a), which methylates CG dinucleotides to repress transcription, and histone deacetylase 1 (Hdac1; Papizan et al. 2011). This NKX2-2/Dnmt3a/Hdac1 complex occupies the Arx promoter and inhibits ARX transcription (Papizan et al. 2011). The β-cell-specific deletion of Dnmt3a (Papizan et al. 2011), or of the related Dnmt1 (Dhawan et al. 2011), predictably resulted in the de-repression of ARX in β cells followed by β-to-α transdifferentiation. As NKX2-2 and the other known components of the ARX repression complex are also expressed in adult ARX+ α cells, there are probably additional β-cell-specific factors that aid in ARX repression in the β cell. In summary, NKX2-2 is required to facilitate endocrine differentiation early in embryonic development. Later in β cell development, NKX2-2 takes on the role of maintaining β cell identity and in this capacity prevents transdifferentiation to the α cell lineage by epigenetically modifying the Arx promoter.

**Maintaining β cell identity through FOXO1 expression**

Another transcription factor that is integral for maintaining β cell identity is FOXO1. While FOXO1 mRNA is similarly expressed in both α and β cells (Bennet et al. 2014), results of immunofluorescence analysis indicate that FOXO1 protein is more restricted to β cells (Kitamura et al. 2009). In β cells, FOXO1 is normally found in the cytoplasm, but mild hyperglycemia causes nuclear translocation of FOXO1 (Talchait et al. 2012), possibly contributing to the maintenance of MAFA and NEUROD1 expression and preservation of β cell function (Kitamura et al. 2005). Indeed, ablation of Foxo1 from β cells via rat Ins2-Cre (Herrera 2000) increases susceptibility of β cells to metabolic stress.
Human β-to-α transdifferentiation without genetic manipulation of transcription factor expression

The effects of the specific genetic manipulations described earlier in this review indicate the importance of transcription factors in the transdifferentiation process. Human β cells show unexpected plasticity as they too have the capacity to convert into α cells, and apparently do so without genetic perturbation of transcription factor networks. This was demonstrated by irreversibly labeling more than 80% of β cells by transducing dissociated human islets with lentiviral vectors containing a rat Ins2-Cre and a GFP reporter (Russ et al. 2009), with less than 1% of α cells being labeled (Spijker et al. 2013). Following labeling, the dissociated cells were re-associated into islet-like clusters. Over the course of 2 weeks, the percentage of β cells in these clusters declined and that of α cells increased. Low levels of both apoptosis and proliferation indicated that these processes are not major contributors to the changing cluster composition. Instead, up to 15% of α cells showed a β cell lineage mark 2 weeks following transduction (Spijker et al. 2013). Generalized inhibition of ARX in the cultures reduced the percentage of α cells carrying a β cell lineage label, while at the same time increasing the number of remaining β cells with a lineage label. This was interpreted as a reduction in β-to-α transdifferentiation and, given the central role of ARX in the α cell, could also be due in part to a loss of α cells (Spijker et al. 2013). No cells that co-expressed insulin and glucagon were found. Instead, β cells degranulated before expressing glucagon and did so despite the continued presence of PDX1 and NKX6-1 (Spijker et al. 2013), β-cell-specific transcription factors that inhibit glucagon expression (Schisler et al. 2005). The α cell identity persisted for at least 2 weeks after transplantation into mice (Spijker et al. 2013). These results indicate that human β cells, similar to those in mouse, have the capacity to transdifferentiate into α cells, at least under experimental conditions in vitro and dependent on ARX. The question as to whether such plasticity of endocrine cell types exists in the human islet in situ remains yet to be answered.

Transdifferentiation of α to β cells

Forcing α-to-β transdifferentiation by over-expression of PAX4

As β cells transdifferentiate into α cells as a result of forced ARX expression and with the knowledge that ARX and PAX4 play opposing roles in the differentiation of α and β cells during embryonic development, it follows that the
over-expression of PAX4 might promote a ß cell identity. PAX4 is normally expressed only in the subset of endocrine cells that will become ß and á cells (Sosa-Pineda et al. 1997) and is undetectable in adult mouse islets (Smith et al. 1999, Benner et al. 2014). Cre-recombinase-mediated over-expression of PAX4 in the PDX1 domain (all pancreas cell types), the PAX6 domain (all endocrine cells), or the glucagon domain (á cells) invariably reduced á cell numbers (Collombat et al. 2009). Despite decreased á cell numbers, blood glucose levels remained normal or were slightly repressed at birth, although glucose clearance was improved in line with reduced glucagon tone (Collombat et al. 2009). Results of lineage tracing in mice with PAX4 over-expression in the á cell revealed that á cells were lost through their transdifferentiation into ß cells. An unforeseen effect was the development of progressive hyperglycemia, despite increased ß cell mass and reduced á cell numbers (Collombat et al. 2009). This paradoxical observation probably relates to the continued over-expression of PAX4 by ß cells, which is normally absent from adult mouse ß cells (Fig. 2; Smith et al. 1999, Benner et al. 2014). Over-expression of PAX4 in ß cells induces ß cell proliferation via expression of the oncogene c-myc, but impairs glucose-stimulated insulin secretion (Brun et al. 2004), consistent with C-Myc repressing the protein levels of insulin, SLC2A2, and PDX1 (Cheung et al. 2010). The combined effects of PAX4 over-expression and c-MYC induction appear to cause partial dedifferentiation and thus explain the phenomenon of ß cell failure despite increased ß cell mass in PAX4-over-expressing ß cells.

Deletion of ARX from á cells results in loss of á cell phenotype

Transdifferentiation from á to ß can also be induced independently of PAX4 over-expression in ß cells by deleting Arx from á cells via glucagon-Cre-mediated recombination (Herrera 2000) of a floxed Arx allele (Fulp et al. 2008). This results in á-to-ß transdifferentiation (Courtney et al. 2013, Wilcox et al. 2013). One group reported continued á cell neogenesis from a proposed ductal progenitor and enlargement of islets over time (Courtney et al. 2013), whilst the other observed no differences in total hormone-positive-cell numbers, possibly due to the younger ages of mice examined as well as a much lower observed efficiency of Cre recombination (Wilcox et al. 2013). In contrast to the over-expression of PAX4 in á cells, which precipitates hyperglycemia, presumably attributable to continuation of forced PAX4 expression upon á-to-ß cell transdifferentiation, deletion of Arx in á cells improves glucose tolerance (Courtney et al. 2013). Combined deletion of Pax4 and Arx from the á cell produced a phenotype similar to that resulting from Arx deletion alone. This indicates that while PAX4 and ARX transcriptionally repress each other (Collombat et al. 2003) and global deletion of both Arx and Pax4 results in a lack of both á and ß cells (Collombat et al. 2005), á cells can transdifferentiate into ß cells upon loss of Arx in the absence of Pax4 (Courtney et al. 2013). These results, combined with the above-mentioned roles for ARX, indicate that ARX is a key driver of á cell differentiation and maintenance as well as transdifferentiation of ß cells-to-á cells.

Maintaining á cell identity through expression of MEN1 tumor suppressor

An interesting example of possible á-to-ß cell transdifferentiation in the human pancreas is found in patients with MEN syndrome, caused by mutations in the MEN1 tumor suppressor gene. MEN1 is important for normal development of all islet cell lineages (Fontaniere et al. 2008). MEN syndrome patients present with tumors of various endocrine organs (Lemos & Thakker 2008). The development of MEN1 tumors is likely to be a multistep process in which progressive loss of the two alleles of the MEN1 gene precipitates hyperplasia and atypia (with abnormally shaped cells), while the development of full-blown adenomas may require additional somatic mutations (Crabtree et al. 2003). Glucagonomas, while abundant in microadenomas of the pancreas, become increasingly rare as MEN1-deficient tumors grow and insulinomas and mixed islet tumors prevail (Anlauf et al. 2006, Perren et al. 2007). The deletion of MEN1 from the á cell using glucagon-Cre produced a phenotype that resembles that of patients with MEN syndrome. An á-cell-specific deletion resulted in glucagonomas, hyperglucagonemia, and hyperglycemia as expected. Interestingly, MEN1-deficient insulinomas subsequently developed and became the dominant effectors of blood glucose over time (Lu et al. 2010). Such insulinomas developed via a glucagon–insulin double-positive intermediate and the location of the insulin granules within the cell resembled those of glucagon in á cells. Indeed, the results of lineage-tracing experiments were indicative of an á cell origin of these insulinoma cells (Lu et al. 2010). Glucagon–insulin double-positive cells appeared before islet tumors arose, indicating the possibility of a direct MEN1 effect on á cell maintenance, rather than other somatic mutations that are acquired over time. These results not only indicate that á cells in a MEN1-deficient tumor model transdifferentiate
into β cells, but also indicate that a similar process of transdifferentiation may take place in human MEN syndrome patients.

**Near-total β cell ablation replenishes β cells through an α or δ cell source**

Significant loss of β cell mass is accompanied by β cell regeneration, achieved largely through self-duplication of existing β cells in adult mice (Dor et al. 2004). Depletion of approximately 90% of β cells has been shown to result in hyperglycemia and to induce a β cell proliferative response (Cano et al. 2008). However, results of recent studies have indicated that more acute (>90%) β cell loss is able to invoke alternative mechanisms in efforts to replete the β cell deficit. Even more extreme depletion was achieved in a genetic mouse model in which β cells express the diphtheria toxin receptor under the control of the rat insulin 2 promoter (Thorel et al. 2010). Administration of diphtheria toxin resulted in near-total β cell ablation (99.6%; in 2-month-old mice). This extreme loss of β cells triggered α-to-β cell transdifferentiation and was, over time, able to regenerate sufficient β cell mass to restore normoglycemia (Thorel et al. 2010). Results of subsequent work by the same group indicate that near-complete β cell ablation in the juvenile (2-week-old) pancreas triggers a rapid transdifferentiation response from δ cells (Chera et al. 2014). Transdifferentiated β cells of α cell descent expressed insulin and the β cell transcription factors PDX1 and NKX6-1 and proceed through a transient co-positive stage, followed by the loss of glucagon (Thorel et al. 2010). In contrast, transdifferentiated β cells of δ cell descent proceed through a hormone-negative stage before acquisition of insulin expression (Chera et al. 2014). When only 50% of β cells were depleted, no α-to-β cell transdifferentiation was observed (Thorel et al. 2010). The authors therefore suggested that transdifferentiation is induced under circumstances of extreme β cell loss, where β cell self-replication can no longer restore significant β cell mass, with the source of transdifferentiation dependent on the postnatal age of the animal. This age-dependence may stem from differences in α versus δ cell development. The α cells are among the first endocrine cells to differentiate, while the β and δ lineages separate later (Habener et al. 2005, Ben-Othman et al. 2013). Thus, δ and β cells may be more closely related, as exemplified by the continued expression of PDX1 in both cell types (Peshavaria et al. 1994). Perhaps, the β and δ cell lineages are still diverging in early postnatal life, enabling the observed rapid transdifferentiation of δ-to-β cells upon near-total β cell depletion (Chera et al. 2014). As δ cells mature, they may lose the ability to readily transdifferentiate into β cells, leaving the slower process of α-to-β cell conversion to emerge as the main source of new β cells by transdifferentiation.

**Partial α-to-β transdifferentiation in human islets by modulation of epigenetic marks**

In accordance with the importance of epigenetic modifications for maintenance of β cell fate, there is evidence from studies of cultured human islets indicating that the same holds true for α cell fate. The epigenome of the α cells appears to make them more amenable to transdifferentiation (Bramswig et al. 2013). This conclusion is based on the interesting observation that many more genes in the α cell fraction were associated with both activating (H3K4me3) and inhibiting (H3K27me3) histone modifications when compared with β and exocrine cells. Resolution of dual marks into a single mark is a common feature during the course of normal differentiation (Mikkelsen et al. 2007), and the overrepresentation of dual marks in the α cell was interpreted as indicating that the α cell might be poised to change fate (Bramswig et al. 2013). However, the increased prevalence of bivalently labeled genes in the α cell fraction could have been embellished by contaminating β cells. This possibility is difficult to exclude when applying cell-surface markers to purify populations for FACS analysis. Moreover, the study was based on ex vivo conditions that may be far more predisposed to induce transdifferentiation as an artifact of culture. Nevertheless, treatment of human islets with the histone methyltransferase inhibitor Adox resulted in mis-expression of PDX1 in α cells and the induction of glucagon–insulin co-positive cells (Bramswig et al. 2013). Although ectopic expression of α cell transcription factors in β cells under these conditions was not addressed, these observations once more highlight the surprising plasticity that exists among endocrine cells of the mouse and human pancreas.

**Concluding remarks**

Diabetes is characterized by an absolute or relative deficiency of β cells. Thus, increasing β cell mass will be instrumental in restoring normoglycemia in patients. Stimulating human β cell proliferation has proven challenging, even when results from rodent models seemed promising (Kulkarni et al. 2012, Bernal-Mizrachi et al. 2014). Moreover, particularly in later stages of T1D, the dearth of residual β cells in combination with their notoriously slow proliferation rate makes the restoration
of β cell mass through the stimulation of β cell proliferation a tall order. Direct transplantation of β cells in the form of islets or whole pancreas has proven more successful in managing diabetes but is hindered by: i) a lack of donor material and ii) the requirement for life-long immunosuppression (Shapiro 2012). Efforts to generate mature, functional β cells from induced pluripotent or embryonic stem cells are in full swing (Kelly et al. 2011, Pagliuca et al. 2014, Rezania et al. 2014), but will have many safety hurdles to overcome. Alternative sources of new β cells, including ductal, acinar, and, most recently, non-β endocrine cells, provide alternative strategies for treating diabetes (Lysy et al. 2013). Together these efforts have revealed a remarkable degree of plasticity among the different endocrine cells of the islet and have firmly established that transdifferentiation takes place under certain experimental circumstances in mouse models.

The dynamic landscape of identity switches that is now coming to light offers hope for novel therapeutic strategies with which to treat diabetes. The α-to-β cell transdifferentiation, in particular, is not only an avenue for the (partial) restoration of β cell mass, but it also simultaneously reduces α cell mass and thus potentially restores the balance between insulin and glucagon, which is perturbed in diabetes (Unger & Orci 2010, Unger & Cherrington 2012). While non-islet cells far outnumber islet cells as a potential source for new β cells, non-β islet cells may be more amenable to transdifferentiation into β cells than duct or acinar cells, because they share a more recent progenitor in development. Moreover, non-β endocrine cells functionally resemble β cells in many ways, which is reflected in a high degree of overlap in expression between many of the genes that are required for glucose sensing, stimulus–secretion coupling, and exocytosis (Benner et al. 2014).

In order to capitalize on the potential for transdifferentiation in the islet, important questions remain unanswered that will undoubtedly be addressed in future. Firstly, it remains to be demonstrated that individual transdifferentiated β cells have fully completed their transdifferentiation and are therefore functionally equivalent to endogenous β cells. Secondly, it is imperative to identify molecules that can channel transdifferentiation toward the desired outcome of increased β cell mass by promoting α- or δ-to-β cell transdifferentiation, while preventing the transdifferentiation or dedifferentiation of β cells. Finding such molecules and ways to deliver them to the pancreas is essential to replace strategies that relied on genetic manipulation to establish proof-of-principle for transdifferentiation in the islet. Whether these molecules will be as efficient as transcription factors at inducing transdifferentiation is a separate question and is related to the question of phenotype stability for these molecules. While the possibility of depleting the islet of α and/or δ cells is a potential concern, the identification of druggable targets that can induce islet cell transdifferentiation remains the more immediate challenge, before we worry about the consequences of succeeding at this task. We are encouraged by these new opportunities despite the fact that such key questions regarding transdifferentiation in the islet remain unanswered as yet.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

MOH is the recipient of a Career Development Award from the Juvenile Diabetes Research Foundation (JDRF) and received support from grants 17-2012-424 and 2-2013-54 from the JDRF, P01-DK026741 from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK), and the Clayton Medical Research Foundation, Inc.

References


Murtzaq LA, Song YZ, Kwon EM & Melton DA 2003 Notch signaling controls multiple steps of pancreatic differentiation. PNAS 100 14920-14925. (doi:10.1073/pnas.2436557100)


Ohlsson H, Karlsson K & Edlund T 1993 IFIP, a homeodomain-containing transactivator of the insulin gene. EMBO Journal 12 4251–4259.


Sander M, Neubuser A, Alamaras J, Ee HC, Martin GR & German MS 1997 Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes and Development 11 1662–1673. (doi:10.1101/gad.11.11.1662)


Sussel L, Kalamaras J, Hartigan-O’Connor DJ, Meneses JJ, Pedersen RA, Rubenstein JL & German MS 1998 Mice lacking the homeodomain transcription factor Nkx2-2 have diabetes due to arrested differentiation of pancreatic \( \beta \) cells. *Development* **125** 2213–2221.


Received in final form 29 January 2015

Accepted 10 February 2015